THIOPLEX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Thioplex, and what generic alternatives are available?
Thioplex is a drug marketed by Immunex and is included in one NDA.
The generic ingredient in THIOPLEX is thiotepa. There are eleven drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the thiotepa profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Thioplex
A generic version of THIOPLEX was approved as thiotepa by WEST-WARD PHARMS INT on April 2nd, 2001.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for THIOPLEX?
- What are the global sales for THIOPLEX?
- What is Average Wholesale Price for THIOPLEX?
Summary for THIOPLEX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 107 |
| Clinical Trials: | 8 |
| DailyMed Link: | THIOPLEX at DailyMed |
Recent Clinical Trials for THIOPLEX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Baptist Health South Florida | Phase 2 |
| St. Jude Children's Research Hospital | Phase 2 |
| Dana-Farber Cancer Institute | Phase 1/Phase 2 |
US Patents and Regulatory Information for THIOPLEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunex | THIOPLEX | thiotepa | INJECTABLE;INJECTION | 020058-001 | Dec 22, 1994 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for THIOPLEX
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| ADIENNE S.r.l. S.U. | Tepadina | thiotepa | EMEA/H/C/001046 In combination with other chemotherapy medicinal products:with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.". It is proposed that Tepadina must be prescribed by physicians experienced in conditioning treatment prior to haematopoietic progenitor cell transplantation. |
Authorised | no | no | no | 2010-03-15 | |
| Esteve Pharmaceuticals GmbH | Thiotepa Riemser | thiotepa | EMEA/H/C/005434 Thiotepa Riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.Thiotepa Riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients |
Authorised | yes | no | no | 2021-03-26 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
